{
    "clinical_study": {
        "@rank": "53560", 
        "arm_group": {
            "arm_group_label": "Itraconazole", 
            "arm_group_type": "Experimental", 
            "description": "Taken at a dose of 300 mg by mouth twice daily (600 mg a day total)."
        }, 
        "brief_summary": {
            "textblock": "This study is being done to test an investigational drug called itraconazole in the\n      treatment of prostate cancer."
        }, 
        "brief_title": "A Phase II Study of Itraconazole in Biochemical Relapse", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a phase II, single arm study of itraconazole dosed at 300 mg PO BID in patients with\n      noncastrate, non-metastatic, biochemically relapsed prostate cancer after prior definitive\n      local therapy. Simon's two stage minimax design will be followed for accrual and include an\n      interim test for lack of efficacy. There is a pre-specified stopping rule for safety after\n      10 patients have been treated for a minimum of 8 weeks of protocol therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologic confirmation of adenocarcinoma of the prostate\n\n          2. Biochemically relapsed disease with a rising PSA on at least two consecutive\n             measurements at least two weeks apart after prior definitive local therapy (radical\n             prostatectomy, external beam radiation, or brachytherapy) or combination of radical\n             prostatectomy and radiotherapy (RT) with curative intent\n\n          3. Prior primary or salvage radiation or not a candidate for salvage radiation due to\n             patient preference or clinical assessment based upon disease characteristics and/or\n             patient co-morbidities.\n\n          4. Minimum PSA: If no prior androgen deprivation therapy (ADT) for biochemical relapse:\n\n               -  1.0 ng/mL if prior radical prostatectomy with or without adjuvant/salvage\n                  radiation therapy, confirmed by repeat measurement at least 2 weeks later, or\n\n               -  Nadir + 2 ng/mL if prior RT alone without prior radical prostatectomy, confirmed\n                  by repeat measurement at least 2 weeks later If prior ADT for biochemical\n                  relapse:\n\n               -  4.0 ng/mL or > 2 ng/mL above nadir on prior cycle of ADT, whichever is higher,\n                  confirmed by repeat measurement at least 2 weeks later\n\n          5. No evidence of metastatic disease on imaging by whole body bone scan (technetium-99\n             or Na-F PET bone scan) and cross-sectional imaging of the abdomen/pelvis (CT or MRI)\n             within 6 weeks of Day 1 of protocol therapy\n\n          6. Prior androgen deprivation therapy (ADT) with LHRH agonist and/or antagonist allowed\n             for either (neo)adjuvant treatment with local therapy or for biochemical relapse\n\n          7. Last effective dose of LHRH agonist/antagonist \"expired\" > 3 months prior to study\n             entry.\n\n          8. For example, a patient receiving LHRH agonist injection every 3 months would be\n             eligible provided their last injection was > 6 months prior to Day 1 of protocol\n             therapy. A patient receiving LHRH agonist injections every 4 months will be eligible\n             provided last injection was > 7 months prior to Day 1 of protocol therapy.\n\n          9. Serum testosterone level: If no prior androgen deprivation therapy:\n\n             - A single measurement greater than 150 ng/dL within 3 months of day 1 of protocol\n             therapy If prior androgen deprivation therapy (either in adjuvant or biochemical\n             relapse setting):\n\n             The two most recent measurements of serum testosterone prior to Day 1 of protocol\n             therapy must fulfill the following criteria:\n\n               -  Both measurements are greater than 150 ng/dL.\n\n               -  The two measurements are spaced at least 14 days apart.\n\n               -  Both must be measured within 3 months of Day 1 of protocol therapy.\n\n               -  There must not be an increase of > 50 ng/dL between these two successive\n                  measurements.\n\n         10. PSA doubling time (PSADT) \u2264 15 months, calculated based upon all serum PSA\n             measurements obtained within 3 months prior to Day 1 of protocol therapy, with a\n             minimum of three PSA measurements spaced at least 14 days apart (see section 6). PSA\n             values obtained when serum testosterone was known to be less than 150 ng/dL, prior to\n             local therapy, or within three months of last dose of LHRH agonist/antagonist or\n             antiandrogen will be excluded from the calculation of the PSADT. PSADT calculation to\n             be carried out using the following website:\n             http://nomograms.mskcc.org/Prostate/PsaDoublingTime.aspx\n\n         11. Total bilirubin less than 1.5 times upper limit of normal (ULN), or less than 3 times\n             ULN at study entry in a patient with documented Gilbert\u201fs disease.\n\n         12. ALT and AST levels less than 1.5 times ULN at study entry\n\n         13. Serum potassium greater than 3.5 mmol/L without oral supplementation\n\n         14. No history of uncontrolled hypertension (blood pressure > 160/100 mm Hg despite\n             anti-hypertensive medication)\n\n         15. ECOG performance status of 0 or 1\n\n         16. Estimated life expectancy greater than 5 years\n\n         17. Age greater than or equal to 18 years at time of study entry\n\n         18. Ability to sign written informed consent\n\n         19. Ability to swallow study drug whole as a capsule\n\n         20. Primary prostate cancer tissue available for analysis is not required for inclusion\n             onto this study but is strongly encouraged.\n\n        Exclusion Criteria:\n\n          1. Castrate-resistant disease, as evidenced by either:\n\n               -  Rising PSA on 2 consecutive measurements at least 2 weeks apart with concurrent\n                  documented serum testosterone < 50 ng/dL at the time of PSA measurement, or\n\n               -  Rising PSA on 2 consecutive measurements at least 2 weeks apart measured within\n                  3 months after last LHRH agonist/antagonist injection\n\n          2. Prior bilateral orchiectomy\n\n          3. Congestive heart failure of NYHA class III or higher severity at study entry\n\n          4. History of chronic active hepatitis\n\n          5. Grade 2 or higher peripheral neuropathy at the time of study entry\n\n          6. Use of 5-alpha reductase antagonist (i.e. finasteride, dutasteride) or antiandrogen\n             (i.e. flutamide, bicalutamide) within 6 weeks of Day 1 of protocol therapy\n\n          7. Use of systemic steroids at an equivalent dose of prednisone 5 mg/day or higher\n             within 6 weeks of Day 1 of protocol therapy\n\n          8. Use of medications or herbal supplements which are known to potentially lower serum\n             PSA within 6 weeks of Day 1 of protocol therapy\n\n          9. Use of other medications that may potentially interact with itraconazole within 1\n             week of study entry\n\n         10. Use of other investigational agents within 6 weeks of Day 1 of protocol therapy\n\n         11. Prior pathology consistent with small cell carcinoma or prostate cancer with\n             predominantly neuroendocrine differentiation"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01787331", 
            "org_study_id": "CC#125513"
        }, 
        "intervention": {
            "arm_group_label": "Itraconazole", 
            "description": "Itraconazole is available as pink and blue capsules. Itraconazole should be taken with meals or within 30 minutes after a meal.", 
            "intervention_name": "Itraconazole", 
            "intervention_type": "Drug", 
            "other_name": "Sporanox"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "biochemically relapsed", 
            "hormone sensitive", 
            "non-metastatic", 
            "prostate cancer", 
            "after prior definitive local therapy", 
            "PSA", 
            "Hedgehog-signaling pathway"
        ], 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "contact": {
                "email": "mailto:walshp@medicine.ucsf.edu", 
                "last_name": "Paula Dutton", 
                "phone": "415-885-7871"
            }, 
            "contact_backup": {
                "email": "ryanc@medicine.ucsf.edu", 
                "last_name": "Charles Ryan, MD", 
                "phone": "415-353-9279"
            }, 
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94115"
                }, 
                "name": "University of California San Francisco"
            }, 
            "investigator": {
                "last_name": "Charles Ryan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse", 
        "other_outcome": [
            {
                "description": "To determine the mean percent change from baseline in serum androgen levels, including serum testosterone, DHEA-S, and androstenedione, after 4 and 12 weeks of protocol therapy with itraconazole.", 
                "measure": "Endocrine Parameters: Mean Percent Change in Serum Androgen Levels", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "To determine the mean percent change from baseline in additional serum hormone levels, including adrenocorticotropic hormone (ACTH), aldosterone, deoxycorticosterone (DOC), 11-deoxycortisol, and cortisol after 4 and 12 weeks of protocol therapy with itraconazole.", 
                "measure": "Enodrine Parameters: Mean Percent Change in Additional Serume hormone levels", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "To determine if there is a relationship between baseline and/or percent change in serum hormone levels and achieving a decline of > 50% in serum PSA after 12 weeks of protocol therapy.", 
                "measure": "Endocrine Parameters: Determination of Relationship between serum hormone levels and serum PSA decline", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "To  determine  the  proportion  of  patients  treated  with  itraconazole  who  display  a  down - regulation of the Hedgehog pathway, as assessed by measurement of GLI1 mRNA expression by qRT-PCR on serial skin biopsies obtained at baseline and after 4 weeks of protocol therapy. Down-regulation will be defined as a decline of any magnitude in GLI1 mRNA expression after 4 weeks of protocol therapy compared to baseline expression level.", 
                "measure": "Hedgehog Pathway: Determination of Proportion of Patients who display down-regulation of Hedgehog pathway", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "To determine if there is a relationship between down-regulation of the Hedgehog pathway and PSA modulation, including proportion of patients achieving a decline of > 50% in serum PSA as well as time to PSA progression.", 
                "measure": "Hedgehog Pathway: Determination of Relationship between down-regulation of Hedgehod pathway and PSA modulation", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "To evaluate archived primary prostate cancer tissue (biopsy or prostatectomy specimen) for baseline Hedgehog pathway status, using both qRT-PCR-based mRNA expression analysis and protein-based immunohistochemical (IHC) analysis of key Hedgehog pathway components (GLI1, PCTH1, SMO) and Sonic hedgehog ligand.", 
                "measure": "Hedgehog Pathway: Evaluation of tissue for baseline Hedgehog pathway status", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "To determine if there is a relationship between mRNA and IHC expression of components in the Hedgehog pathway in primary prostate cancer tissue and PSA modulation, including the proportion of patients achieving a decline of \u2265 50% in serum PSA as well as time to PSA progression.", 
                "measure": "Hedgehog Pathway: Determination of relationship between expression of components in Hedgehod pathway and PSA modulation", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }
        ], 
        "overall_contact": {
            "email": "walshp@medicine.ucsf.edu", 
            "last_name": "Paula Dutton", 
            "phone": "415-885-7871"
        }, 
        "overall_contact_backup": {
            "email": "ryanc@medicine.ucsf.edu", 
            "last_name": "Charles Ryan, MD", 
            "phone": "415-353-9279"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Francisco", 
            "last_name": "Charles Ryan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine whether the proportion of patients who achieve a \u2265 50% decline in serum PSA after 12 weeks of protocol therapy with itraconazole dosed at 300 mg BID is superior to a historical control based upon the observed PSA response proportion in prior studies of non-castrating systemic therapy in men with biochemically relapsed hormone sensitive prostate cancer. PSA progression will be defined as follows: (1) If no PSA decline is observed on therapy, PSA progression will be defined as an increase in serum PSA > 50% above the baseline PSA, and an absolute increase of > 2 ng/mL above baseline, confirmed by repeat measurement at least 2 weeks later (2) If PSA declines on therapy, PSA progression will be defined as an increase in serum PSA > 50% above the nadir PSA on therapy, and an absolute increase > 2 ng/mL above the nadir, confirmed by repeat measurement at least 2 weeks later.", 
            "measure": "Proportion of Patients Who Achieve Greater than 50% decline in Prostate Specific Antigen", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01787331"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Francisco", 
            "investigator_full_name": "Charles Ryan", 
            "investigator_title": "Genitourinary cancer specialist, Associate Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the median time to PSA progression from the start of protocol therapy with itraconazole among men with biochemically relapsed prostate cancer.", 
                "measure": "Determination of Median Time to PSA Progression", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "To determine the median time to clinical progression measured from the start of protocol therapy with itraconazole among men with biochemically relapsed prostate cancer. Clinical progression will be defined as the first occurrence of either the development of metastases or initiation of non-protocol therapy, and will exclude PSA-only progression. Clinical progression will be defined as the first occurrence of either the development of metastases or initiation of non-protocol therapy, and will exclude PSA-only progression.", 
                "measure": "Determination of Median Time to Clinical Progession", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "To determine the median metastasis-free survival measured from the start of protocol therapy in patients treated with itraconazole for biochemically relapsed prostate cancer.", 
                "measure": "Determination of Median Metastasis-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "To determine the mean percent change from baseline after 12 weeks of protocol therapy compared with pre-treatment in PSA doubling time. The pre-treatment PSA doubling time will be determined based upon all PSA measurements obtained within 3 months prior to Day 1 of protocol therapy, with a minimum of three PSA measurements spaced at least 14 days apart.", 
                "measure": "Determination of Mean Percent Change Compared with pre-treatment in PSA doubling time", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To characterize the safety profile of itraconazole in the biochemically relapsed hormone sensitive prostate cancer population as graded by CTCAE version 4.03.", 
                "measure": "Maximum Grade Toxicities Observed during Treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "description": "To determine the mean steady-state itraconazole with its active metabolite (hydroxy-itraconazole) serum levels after 4 weeks of therapy with itraconazole.", 
                "measure": "Determination of the mean steady-state trough level of serum", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 weeks"
            }
        ], 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Charles Ryan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}